Proprietary IDOSE PlatformThe integrated IDOSE platform combines planning, monitoring and light-delivery for controlled PDT, creating a differentiated, technical barrier to entry. As a platform it supports extension into other solid tumors and recurring procedure revenues, underpinning durable commercial potential.

Low Financial LeverageVery low debt-to-equity reduces financial distress risk and preserves flexibility to raise capital or withstand clinical/commercial delays. This conservative leverage profile is a durable strength that lengthens runway compared with highly levered peers in capital-intensive medtech development.

Improving Free Cash Flow TrendA 40.6% year-over-year improvement in FCF, while still negative, indicates operational progress or cost discipline. If sustained, this trend materially reduces future funding needs and signals management can incrementally improve cash efficiency during commercialization and clinical scaling.

Bears Say

Near-zero RevenueMinimal reported revenue shows the company's technology has not yet achieved meaningful commercial traction. Lack of recurring sales makes unit economics untested, raises execution risk for scaling, and means future viability depends on successful commercialization or further financing.

Persistent Negative Cash FlowSustained large negative OCF and FCF imply ongoing cash burn and the need for repeated funding. This creates dilution risk, constrains investment in sales/clinical activities, and represents a structural financing challenge until the company reaches sustainable positive cash generation.

Widening Operating LossesSubstantially larger and worsening net losses indicate scaling costs or rising operating expenditure outpacing progress. Deepening losses pressure equity, undermine returns, and increase dependence on capital markets; without revenue ramp this trend threatens long-term sustainability.

2OK FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is €6.61M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is Feb 19, 2026 which is in 2 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Nov 13, 2025. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.008.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 722,203,700 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in DE:2OK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.